| Primary |
| Plasma Cell Myeloma |
50.0% |
| Renal Cell Carcinoma |
50.0% |
|
| Pericardial Effusion |
33.3% |
| Soft Tissue Injury |
33.3% |
| White Blood Cell Count Increased |
33.3% |
|
| Secondary |
| Plasma Cell Myeloma |
32.8% |
| Product Used For Unknown Indication |
17.2% |
| Acute Lymphocytic Leukaemia |
12.1% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
12.1% |
| Diffuse Large B-cell Lymphoma |
10.3% |
| Acute Myeloid Leukaemia |
6.9% |
| Acute Leukaemia |
1.7% |
| B Precursor Type Acute Leukaemia |
1.7% |
| Lymphoma |
1.7% |
| Multiple Myeloma |
1.7% |
| Myelodysplastic Syndrome |
1.7% |
|
| White Blood Cell Count Decreased |
12.5% |
| Platelet Count Decreased |
8.3% |
| Pyrexia |
8.3% |
| Abdominal Pain |
4.2% |
| Cardiac Failure Congestive |
4.2% |
| Dizziness |
4.2% |
| Fall |
4.2% |
| Haematochezia |
4.2% |
| Lymphocyte Count Decreased |
4.2% |
| Lymphoma |
4.2% |
| Muscle Spasms |
4.2% |
| Neuropathy Peripheral |
4.2% |
| Orthostatic Hypotension |
4.2% |
| Pain |
4.2% |
| Periodontitis |
4.2% |
| Rash |
4.2% |
| Rash Generalised |
4.2% |
| Renal Failure |
4.2% |
| Sinusitis |
4.2% |
| Skin Ulcer |
4.2% |
|
| Concomitant |
| Plasma Cell Myeloma |
93.0% |
| Product Used For Unknown Indication |
1.6% |
| Lymphoma |
1.1% |
| Plasma Cell Leukaemia |
1.1% |
| Acute Lymphocytic Leukaemia |
0.5% |
| Amyloidosis |
0.5% |
| Non-hodgkin's Lymphoma |
0.5% |
| Plasmacytoma |
0.5% |
| Prophylaxis |
0.5% |
| Transfusion |
0.5% |
|
| White Blood Cell Count Decreased |
12.5% |
| Rash |
10.2% |
| Thrombocytopenia |
8.0% |
| Pneumonia |
6.8% |
| Neuropathy Peripheral |
5.7% |
| Plasma Cell Myeloma |
5.7% |
| Renal Failure |
5.7% |
| Thrombosis |
5.7% |
| Pyrexia |
4.5% |
| Vomiting |
4.5% |
| Hypoaesthesia |
3.4% |
| Pancytopenia |
3.4% |
| Platelet Count Decreased |
3.4% |
| Pruritus |
3.4% |
| Pulmonary Embolism |
3.4% |
| Rash Pruritic |
3.4% |
| Urticaria |
3.4% |
| Anaemia |
2.3% |
| Constipation |
2.3% |
| Deep Vein Thrombosis |
2.3% |
|
